Hospitalized HIV patients benefit from seeing infectious diseases specialists

(Press-News.org) SAN FRANCISCO – When patients with HIV are hospitalized for other conditions, such as a heart problem, surgery or complications of diabetes, mistakes are often made involving their complicated anti-retroviral therapy (ART) regimens. But those errors are more than twice as likely to be corrected when patients are seen by an infectious diseases (ID) physician, suggests a Cleveland Clinic study being presented at IDWeek 2013™ today.

Most patients with HIV are cared for by physicians with HIV expertise in the community, and when they are hospitalized for non-HIV conditions, hospital providers who are unfamiliar with the complexities of HIV therapy may make errors that have an impact on their treatment, from prescribing medications that negatively interact with their ART regimens to providing the wrong dose of medication. The study found those errors can be reduced by employing a variety of interventions, including education, modification of the electronic drug file to help guide the accurate prescribing of medications, and daily medication profile review by a pharmacist specializing in HIV.

Additionally, researchers found involving an infectious diseases physician is key in improving hospital care: Errors were corrected in 68 percent of patients who saw an ID specialist vs. 32 percent of those who did not.

"Most HIV care has shifted from inpatient to outpatient, so hospital providers aren't as familiar with complicated ART regimens – and as a result, medication errors are common," said Elizabeth A. Neuner, PharmD, an ID clinical pharmacist at Cleveland Clinic and lead author of the study. "By enacting a multidisciplinary plan including pharmacists and physicians to prevent errors from happening or correcting them if they did, we were able to significantly reduce errors in ART medications."

In the two-part study, researchers looked at 162 patients with HIV who were treated in the hospital before the interventions were put in place, and 110 patients who were treated after changes were made. Errors – meaning guideline recommendations weren't followed – were made 50 percent of the time before interventions were put in place and 34 percent of time time after. When errors were made, they were resolved 36 percent in the pre-interventions group and 74 percent of the time in the interventions group. Errors were corrected much more quickly in the intervention group: an average of 23 hours, vs. 180 hours in the pre-intervention group.

Corrections varied, for example: prescribing accurate ART medication and dosage; adjusting the regimen because a new medication (such as for heart problems or diabetes) was interacting with one of the ART medications; and revising the therapy due to address a new problem, such as kidney injury. In some cases, physicians opted not to correct the error because the patient was doing well on the therapy and the benefits outweighed the risks.

ART regimens often involve a combination of three or more medications that are taken several times a day. ID specialists identified medication errors and resolved them such as by changing the dose or frequency of medication, or adding a medication that was missing, said Dr. Neuner.

### Co-authors of the study being presented at IDWeek by Dr. Neuner are Jamie Sanders, PharmD, Andrea Pallotta, PharmD, Seth Bauer, PharmD, Jennifer Sekeres, PharmD, Ramona Davis, PharmD and Alan Taege, MD.

About IDWeek IDWeek 2013™ is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme "Advancing Science, Improving Care," IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2013 takes place October 2-6 at the Moscone Center in San Francisco. For more information, visit http://www.idweek.org, follow us on Twitter @IDWeek2013 or like us on Facebook at IDWeek.